The potential of aptamers as anticoagulants

Trends in Cardiovascular Medicine

Volumn 15, Issue 1, 2005, Pages 41-45

  Nimjee, Shahid M ^a   Rusconi, Christopher P ^a,b   Harrington, Robert A ^a   Sullenger, Bruce A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Regado Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APTAMER; ARC 183; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING FACTOR IXA INHIBITOR; ENOXAPARIN; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PEGAPTANIB; PROTAMINE; PROTEIN INHIBITOR; RECOMBINANT HIRUDIN; REG 1; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANTICOAGULANTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FACTOR IX; HEMORRHAGE; HUMANS; OLIGONUCLEOTIDES;

EID: 15744384868     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2005.01.002     Document Type: Review

References (28)

1. L.C. Bock, L.C. Griffin, J.A. Latham, E.H. Vermaas, and J.J Toole Selection of single-stranded DNA molecules that bind and inhibit human thrombin Nature 355 1992 564 566
2. S.R. Coughlin Thrombin signalling and protease-activated receptors Nature 407 2000 258 264
3. A. DeAnda Jr., S.E. Coutre, and M.R. Moon Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass Ann Thor Surg 58 1994 344 350
4. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
5. Eyetech Study Group Preclinical and Phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration Retina 22 2002 143 152
6. Eyetech Study Group Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results [comment] Ophthalmology 110 2003 979 986
7. J.A. Ginsberg, M.A. Crowther, R.H. White, and T.L. Ortel Anticoagulation therapy Hematology 1 2001 339 357
8. L. Gold, B. Polisky, O. Uhlenbeck, and M. Yarus Diversity of oligonucleotide functions Annu Rev Biochem 64 1995 763 797
9. E.S. Gragoudas, A.P. Adamis, J. Cunningham, and E.T. Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
10. C.B. Granger, J. Hirsch, and R.M. Califf Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial Circulation 93 1996 870 878
11. L.C. Griffin, G.F. Tidmarsh, L.C. Bock, J.J. Toole, and L.L. Leung In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits Blood 81 1993 3271 3276
12. R.A. Harrington Developing drugs to prevent and treat arterial thrombosis Cardiol Rounds 7 2003 7
13. R.A. Harrington, R.C. Becker, and M. Ezekowitz Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl. 3 2004 513S 548S
14. J. Hirsh, S.S. Anand, and J.L. Halperin Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association Circulation 103 2001 2994 3018
15. D. Jellinek, L.S. Green, and C. Bell Potent 2′-amino-2′- deoxypyrimidine RNA inhibitors of basic fibroblast growth factor Biochemistry 34 1995 11,363 11,372
16. H.U. Jones, J.B. Muhlestein, and K.W. Jones Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports Circulation 106 Suppl. 1 2002 I19 I22
17. A.M. Lincoff, J.A. Bittl, and R.A. Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial [see comment] [published erratum appears in JAMA 289:1638 (2003)] JAMA 289 2003 853 863
18. S. Moll, and H.R. Roberts Overview of anticoagulant drugs for the future Semin Hematol 39 2002 145 157
19. J.J. Popma, P. Berger, and E.M. Ohman Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl. 3 2004 576S 599S
20. S.V. Rao, J.G. Jollis, and R.A. Harrington Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes [see comment] JAMA 292 2004 1555 1562
21. J. Ruckman, L.S. Green, and J. Beeson 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J Biol Chem 273 1998 20,556 20,567
22. C.P. Rusconi, A. Yeh, and H.K. Lyerly Blocking the initiation of coagulation by RNA aptamers to factor VIIa Thromb Haemost 84 2000 841 848
23. C.P. Rusconi, E. Scardino, and J. Layzer RNA aptamers as reversible antagonists of coagulation factor IXa [see comment] Nature 419 2002 90 94
24. C.P. Rusconi, J.D. Roberts, and G.A. Pitoc Antidote-mediated control of an anticoagulant aptamer in vivo Nat Biotechnol 22 2004 1423 1428
25. A.E. Schmidt, and S.P. Bajaj Structure-function relationships in Factor IX and Factor IXa Trends Cardiovasc Med 13 2003 39 45
26. C.E. Tucker, L.S. Chen, and M.B. Judkins Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys Chromatogr B Biomed Sci Appl 732 1999 203 212
27. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
28. T.E. Warkentin, and A. Greinacher Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl. 3 2004 311S 337S